As CMS Chief, Brooks-LaSure Could Turn Quickly To Medicare Drug Spending Reforms
Executive Summary
Chiquita Brooks-LaSure would be in a key position to implement the Biden Administration’s drug pricing priorities and is familiar with the balancing act needed when considering competing interests among stakeholders as policies are shaped.
You may also be interested in...
Medicare Drug Pricing Demonstration Agenda May Be Reshaped By Fowler As CMMI Head
Elizabeth Fowler brings combination of Capitol Hill, White House and pharma industry experience to the role of director of the Center for Medicare and Medicaid Innovation.
Medicaid Rebate Reform: A Sign Of Minimal Drug Pricing Threats Or A Warning Of More To Come?
House Democrats push to remove the current limit on Medicaid rebates in upcoming COVID-19 relief package would likely leave many drug companies unscathed, but some expect bigger ticket drug pricing items will soon be on the agenda.
CMS Administrator Search: 3 Obama-Era Officials Being Considered To Lead Biden’s Medicare Agency
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: